• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过分子动力学和结合自由能计算深入了解E35D HIV-1蛋白酶突变中的安普那韦耐药性

Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations.

作者信息

Meiselbach Heike, Horn Anselm H C, Harrer Thomas, Sticht Heinrich

机构信息

Abteilung für Bioinformatik, Institut für Biochemie, Emil-Fischer-Zentrum, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.

出版信息

J Mol Model. 2007 Feb;13(2):297-304. doi: 10.1007/s00894-006-0121-3. Epub 2006 Jun 23.

DOI:10.1007/s00894-006-0121-3
PMID:16794810
Abstract

Drug resistance is a very important factor contributing to the failure of current HIV therapies. The ability to understand the resistance mechanism of HIV-protease mutants may be useful in developing more effective and longer lasting treatment regimens. In this paper, we report the first computational study of the clinically relevant E35D mutation of HIV-1 protease in its unbound conformation and complexed with the clinical inhibitor amprenavir and a sample substrate (Thr-Ile-Met-Met-Gln-Arg). Our data, collected from 10 ns molecular-dynamics simulations, show that the E35D mutation results in an increased flexibility of the flaps, thereby affecting the conformational equilibrium between the closed and semi-open conformations of the free protease. The E35D mutation also causes a significant reduction of the calculated binding free energies both for substrate and amprenavir, thus giving a plausible explanation for its ability to increase the level of resistance. One possible explanation for the emergence of this mutation, despite its unfavorable effect on substrate affinity, might be the role of E35D as an escape mutation, which favors escape from the immune system in addition to conferring drug resistance.

摘要

耐药性是导致当前抗HIV疗法失效的一个非常重要的因素。了解HIV蛋白酶突变体的耐药机制,对于开发更有效、更持久的治疗方案可能会有所帮助。在本文中,我们报告了对HIV-1蛋白酶临床上相关的E35D突变的首次计算研究,该突变处于未结合构象,并与临床抑制剂安普那韦和一种样本底物(苏氨酸-异亮氨酸-甲硫氨酸-甲硫氨酸-谷氨酰胺-精氨酸)形成复合物。我们从10纳秒的分子动力学模拟中收集的数据表明,E35D突变导致瓣片的灵活性增加,从而影响游离蛋白酶在闭合构象和半开放构象之间的构象平衡。E35D突变还导致底物和安普那韦的计算结合自由能显著降低,从而为其增加耐药水平的能力提供了一个合理的解释。尽管这种突变对底物亲和力有不利影响,但其出现的一个可能解释可能是E35D作为一种逃逸突变的作用,除了赋予耐药性外,它还有利于逃避免疫系统。

相似文献

1
Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations.通过分子动力学和结合自由能计算深入了解E35D HIV-1蛋白酶突变中的安普那韦耐药性
J Mol Model. 2007 Feb;13(2):297-304. doi: 10.1007/s00894-006-0121-3. Epub 2006 Jun 23.
2
A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.一项关于 HIV-1 蛋白酶与达芦那韦、安普那韦、茚地那韦和沙奎那韦复合物因 flap 突变 I50V 导致耐药机制的贡献:系统 MM-PBSA 和热力学积分研究。
J Chem Inf Model. 2013 Aug 26;53(8):2141-53. doi: 10.1021/ci4002102. Epub 2013 Jul 24.
3
Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.野生型和双突变型HIV-1蛋白酶与安普那韦及两种安普那韦相关抑制剂复合的分子动力学和自由能研究:结合及耐药机制
J Med Chem. 2007 Mar 22;50(6):1177-88. doi: 10.1021/jm0609162. Epub 2007 Feb 15.
4
Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.克服HIV-1化疗中的耐药性:安普那韦和TMC-126与HIV-1蛋白酶野生型及耐药突变体的结合热力学
Protein Sci. 2002 Aug;11(8):1908-16. doi: 10.1110/ps.0206402.
5
Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.探索V32I和M46L突变型HIV-1蛋白酶对抑制剂TMC114的耐药性:瓣片动力学和结合机制
J Mol Graph Model. 2015 Mar;56:60-73. doi: 10.1016/j.jmgm.2014.11.003. Epub 2014 Dec 5.
6
Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.PR20 HIV-1 蛋白酶的多药耐药谱归因于扭曲的构象和药物结合景观:分子动力学见解。
J Biomol Struct Dyn. 2016;34(1):135-51. doi: 10.1080/07391102.2015.1018326. Epub 2015 Mar 27.
7
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.耐药性突变对HIV-1蛋白酶动力学特性的影响以及安普那韦和达芦那韦的抑制作用。
Sci Rep. 2015 May 27;5:10517. doi: 10.1038/srep10517.
8
HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.挽救治疗期间与安普那韦耐药相关的HIV蛋白酶突变:I54M的重要性
J Clin Virol. 2004 May;30(1):62-7. doi: 10.1016/j.jcv.2003.08.013.
9
Kinetic and thermodynamic characterisation of HIV-protease inhibitors against E35D↑G↑S mutant in the South African HIV-1 subtype C protease.对南非 HIV-1 亚型 C 蛋白酶中 E35D↑G↑S 突变体的 HIV 蛋白酶抑制剂的动力学和热力学特性进行了研究。
J Enzyme Inhib Med Chem. 2019 Dec;34(1):1451-1456. doi: 10.1080/14756366.2019.1636234.
10
Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.HIV-1蛋白酶中I50V突变赋予的安普那韦耐药性可被N88S突变抑制。
Clin Infect Dis. 2003 Nov 1;37(9):1273-4. doi: 10.1086/378894.

引用本文的文献

1
Integrative Computational Approaches for Understanding Drug Resistance in HIV-1 Protease Subtype C.用于理解HIV-1蛋白酶C亚型耐药性的综合计算方法
Viruses. 2025 Jun 16;17(6):850. doi: 10.3390/v17060850.
2
Premature Activation of the HIV-1 Protease Is Influenced by Polymorphisms in the Hinge Region.HIV-1 蛋白酶的过早激活受铰链区多态性的影响。
Viruses. 2024 May 26;16(6):849. doi: 10.3390/v16060849.
3
HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics.

本文引用的文献

1
Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug Resistance.HIV-1 蛋白酶的分子动力学模拟提示了导致耐药性的不同机制。
J Chem Theory Comput. 2005 Mar;1(2):315-24. doi: 10.1021/ct049869o.
2
Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.1型人类免疫缺陷病毒蛋白酶对奈非那韦的耐药机制。
J Phys Chem B. 2005 Jan 13;109(1):565-74. doi: 10.1021/jp046860+.
3
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA.
带有 10 种洛匹那韦和达芦那韦耐药突变的 HIV-1 蛋白酶表现出改变的抑制、结构重排和极端动力学。
J Mol Graph Model. 2022 Dec;117:108315. doi: 10.1016/j.jmgm.2022.108315. Epub 2022 Sep 1.
4
Drug resistance mutations in protease gene of HIV-1 subtype C infected patient population.HIV-1 C亚型感染患者群体蛋白酶基因中的耐药性突变
Virusdisease. 2021 Sep;32(3):480-491. doi: 10.1007/s13337-021-00725-z. Epub 2021 Jul 13.
5
Elasticity-Associated Functionality and Inhibition of the HIV Protease.弹性相关功能和 HIV 蛋白酶的抑制作用。
Adv Exp Med Biol. 2022;1371:79-108. doi: 10.1007/5584_2021_655.
6
Structural Studies of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of Distal Mutations on Flap Dynamics.对合理选择的多药耐药HIV-1蛋白酶的结构研究揭示了远端突变对瓣片动力学的协同作用。
PLoS One. 2016 Dec 16;11(12):e0168616. doi: 10.1371/journal.pone.0168616. eCollection 2016.
7
Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.关于HIV-1蛋白酶非活性位点突变V77I导致奈非那韦耐药性分子机制的结构研究
BMC Bioinformatics. 2015;16 Suppl 19(Suppl 19):S10. doi: 10.1186/1471-2105-16-S19-S10. Epub 2015 Dec 16.
8
Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody.一种中和性人源抗体识别人类巨细胞病毒糖蛋白B的结构基础。
PLoS Pathog. 2014 Oct 9;10(10):e1004377. doi: 10.1371/journal.ppat.1004377. eCollection 2014 Oct.
9
The role of select subtype polymorphisms on HIV-1 protease conformational sampling and dynamics.特定亚型多态性对HIV-1蛋白酶构象采样和动力学的作用。
J Biol Chem. 2014 Jun 13;289(24):17203-14. doi: 10.1074/jbc.M114.571836. Epub 2014 Apr 17.
10
Mutations in herpes simplex virus gD protein affect receptor binding by different molecular mechanisms.单纯疱疹病毒gD蛋白的突变通过不同的分子机制影响受体结合。
J Mol Model. 2014 Apr;20(4):2192. doi: 10.1007/s00894-014-2192-x. Epub 2014 Mar 20.
细胞毒性T淋巴细胞逃逸变体的传播与积累导致了HIV多态性与人类白细胞抗原之间的负相关。
J Exp Med. 2005 Mar 21;201(6):891-902. doi: 10.1084/jem.20041455.
4
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.安普那韦或福沙那韦联合利托那韦用于治疗HIV感染:药理学、疗效及耐受性概述
Drugs. 2005;65(5):633-59. doi: 10.2165/00003495-200565050-00005.
5
Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.通过分子动力学和绝对结合自由能计算研究第二代HIV-1蛋白酶抑制剂的效率。
Proteins. 2004 Nov 1;57(2):279-93. doi: 10.1002/prot.20192.
6
CD8+ T lymphocyte responses target functionally important regions of Protease and Integrase in HIV-1 infected subjects.在HIV-1感染的受试者中,CD8 + T淋巴细胞反应靶向蛋白酶和整合酶的功能重要区域。
J Transl Med. 2004 May 21;2(1):15. doi: 10.1186/1479-5876-2-15.
7
Development and testing of a general amber force field.一种通用琥珀力场的开发与测试。
J Comput Chem. 2004 Jul 15;25(9):1157-74. doi: 10.1002/jcc.20035.
8
HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.野生型和V82F/I84V突变体的HIV-1蛋白酶分子动力学:对耐药性的可能贡献及潜在的药物新靶点
Protein Sci. 2004 Apr;13(4):1108-23. doi: 10.1110/ps.03468904.
9
HIV evolution: CTL escape mutation and reversion after transmission.HIV进化:传播后的CTL逃逸突变与回复突变
Nat Med. 2004 Mar;10(3):282-9. doi: 10.1038/nm992. Epub 2004 Feb 8.
10
Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype.HLA B44超型多个分子结合能力的同步预测
J Immunol. 2003 Dec 1;171(11):5964-74. doi: 10.4049/jimmunol.171.11.5964.